BRCA1 and breast cancer: Recently, a phase 3 study of 1836 patients, including 6 men, with high clinical-risk BC and germline variant pathogenic or likely pathogenic mutations in BRCA1/2 had increased invasive disease-free survival with adjuvant olaparib for 1 year (38).